<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-1366</identifier>
<setSpec>0001-6519</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Utility of the RET prot-oncogene in the diagnosis of the hereditary medullary thyroid carcinoma. Correlation with the surgical results</dc:title>
<dc:description xml:lang="en">In about 25% of cases medullary thyroid carcinoma (MTC) is hereditary. In this group is possible to detect germline point mutations of the RET proto-oncogene in about 95% of the studied cases. The purpose of the present paper is to confirm the value of the RET in the screening of the hereditary MTC. We studied 43 subjects at risk for a Multiple Endocrine Neoplasia Type 2A Syndrome. RET analysis was positive for MEN 2A in 22 subjects. Fifteen of the 22 have undergone a total thyroidectomy at our facility. Histopathological study of the surgical specimens confirmed the presence of a MTC in all the cases. According with our experience. RET analysis is a 100% sensitive and specific method of hereditary MTC screening, and we think it has obvious advantages over the calcitonin tests in technical, economic and ethic aspects (AU)</dc:description>
<dc:publisher>Sanidad y Ediciones (SANED, S.L.)</dc:publisher>
<dc:description xml:lang="es">Un 25 por ciento de los carcinomas medulares de tiroides (CMT) son de carácter hereditario, y en el 95 por ciento de los mismos se puede detectar una mutación en el proto-oncogen RET. El objeto de este trabajo es la evaluación del RET como método de despistaje del CMT hereditario. Se estudiaron 43 sujetos con riesgo de padecer un MEN 2A. En 22 pacientes el estudio del RET determinó la sospecha de un CMT, 15 de los cuales fueron intervenidos en nuestro hospital, confirmándose en todos ellos la existencia de un CMT. De acuerdo con nuestra experiencia quirúrgica, el despistaje familiar mediante el uso del RET es 100 por ciento sensible y específico, y aporta ventajas metodológicas, económicas y sociales sobre el empleo de la calcitonina (AU)</dc:description>
<dc:source>Acta Otorrinolaringol Esp;52(1): 57-63, ene. 2001. graf, tab</dc:source>
<dc:title xml:lang="es">Utilidad del proto-oncogen RET en el diagnóstico del carcinoma medular de tiroides de tipo hereditario. Correlación con los hallazgos quirúrgicos</dc:title>
<dc:type>article</dc:type>
<dc:creator>Matías Guiu, X</dc:creator>
<dc:creator>Alfayate, R</dc:creator>
<dc:creator>Lagarda, H</dc:creator>
<dc:creator>Malluguiza, R</dc:creator>
<dc:creator>Girbés, J</dc:creator>
<dc:creator>Carreño, M</dc:creator>
<dc:creator>Tudela, J</dc:creator>
<dc:creator>Serrano, S</dc:creator>
<dc:language>es</dc:language>
<dc:identifier>ibc-1366</dc:identifier>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d10568</dc:subject>
<dc:subject>^d29309</dc:subject>
<dc:subject>^d36219</dc:subject>
<dc:subject>^d22696^s22016</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d31146^s22033</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d31589^s22016</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d22696^s22033</dc:subject>
<dc:subject>^d31589^s22033</dc:subject>
<dc:date>200101</dc:date>
</metadata>
</record>
</ibecs-document>
